0
     

Report Added
Report already added
Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027

The cell therapy technologies market is projected to reach USD 8.0 Billion by 2027 from USD 4.0 Billion in 2022, at a CAGR of 14.6% during the forecast period. The growth can be attributed to the increasing public-private partnerships. Several government and private organizations have made significant investments to strengthen R&D in cell therapy leading to surge in cell therapy technologies demand, hence propelling market growth.

“The cell preservation and distribution and handling process segment accounted for the second largest share of the market in 2021”

Cell preservation and distribution is an essential and vital step in the cell scaling-up process. In addition, with the growth in the demand for cell-based medical products and therapies, the demand for reliable storage equipment to preserve finite cell lines and cells manufactured in excess is expected to increase. This factor is expected to drive the growth of this market segment.

“The CROs and CMOs accounted for the second largest share of the cell therapy technologies market in 2021”

To cater the large demand, pharmaceutical companies need to speed up clinical timelines, maintain business continuity, and free up resources for projects. This has increased outsourcing analytical tests to CROs and CMOs, thereby boosting the segment market growth.

Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US), are some of the major players operating in the market.

“Asia Pacific: The fastest-growing region in the cell therapy technologies market”

The Asia Pacific market is expected to register the highest CAGR during the forecast period. Some of the major factors contributing to the growth of the Asia Pacific market are low-cost manufacturing advantage, increasing per capita income, and growing need to curb cancer. In addition, the growth of geriatric population is also fueling the cell therapy technologies market in the region.

The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 80% and Demand Side - 20%
•By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
•By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:
•Thermo Fisher Scientific, Inc. (US)
•Merck KGaA (Germany)
•Danaher Corporation (US)
•Lonza Group (Switzerland)
•Sartorius AG (Germany)
•Terumo BCT (US)
•Becton, Dickinson and Company (US)
•Fresenius SE & Co. KGaA (Germany)
•Avantor, Inc. (US)
•Bio-Techne Corporation (US)
•Corning Incorporated (US)
•FUJIFILM Irvine Scientific (US)
•MaxCyte Inc. (US)
•Werum IT Solutions GmbH (Germany)
•RoosterBio Inc. (US)
•SIRION Biotech GmbH (Germany)
•TrakCel (UK)
•L7 Informatics, Inc. (US)
•Miltenyi Biotec GmbH (Germany)
•STEMCELL Technologies (Canada)
•GPI Iberia (Spain)
•MAK-SYSTEM (US), OrganaBio, LLC (US)
•IxCells Biotechnology (China)
•Wilson Wolf Manufacturing Corporation (US)

Research Coverage:
This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments such as the product, process, cell type, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
Table of Contents

1INTRODUCTION31
1.1STUDY OBJECTIVES31
1.2MARKET DEFINITION31
1.2.1INCLUSIONS AND EXCLUSIONS32
1.3MARKET SCOPE32
1.3.1MARKETS COVERED32
FIGURE 1CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION32
1.3.2YEARS CONSIDERED33
1.4CURRENCY CONSIDERED33
1.5LIMITATIONS33
1.6STAKEHOLDERS34
1.7SUMMARY OF CHANGES34
2RESEARCH METHODOLOGY35
2.1RESEARCH DATA35
FIGURE 2RESEARCH DESIGN35
2.1.1SECONDARY DATA36
2.1.2PRIMARY DATA36
FIGURE 3BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: CELL THERAPY TECHNOLOGIES MARKET37
2.2MARKET ESTIMATION METHODOLOGY38
FIGURE 4CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 202138
FIGURE 5MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 202138
2.2.1INSIGHTS FROM PRIMARY EXPERTS39
FIGURE 6MARKET SIZE VALIDATION FROM PRIMARY SOURCES39
2.3MARKET GROWTH RATE PROJECTIONS40
FIGURE 7CELL THERAPY TECHNOLOGIES MARKET (SUPPLY SIDE): CAGR PROJECTIONS41
FIGURE 8CELL THERAPY TECHNOLOGIES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS42
2.4DATA TRIANGULATION43
FIGURE 9DATA TRIANGULATION METHODOLOGY43
2.5RESEARCH ASSUMPTIONS44
2.6RISK ANALYSIS44
3EXECUTIVE SUMMARY45
FIGURE 10CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)45
FIGURE 11CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022 VS. 2027 (USD MILLION)46
FIGURE 12CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION)46
FIGURE 13CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)47
FIGURE 14GEOGRAPHICAL SNAPSHOT OF CELL THERAPY TECHNOLOGIES MARKET48
4PREMIUM INSIGHTS49
4.1CELL THERAPY TECHNOLOGIES MARKET OVERVIEW49
FIGURE 15INCREASING GOVERNMENT INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH49
4.2ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SHARE, BY CELL TYPE AND COUNTRY (2021)50
FIGURE 16T CELLS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 202150
4.3CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2022 VS. 202750
FIGURE 17MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 202750
4.4CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PROCESS, 202251
FIGURE 18CELL PROCESSING SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 202251
4.5CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES51
FIGURE 19ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD51
5MARKET OVERVIEW52
5.1INTRODUCTION52
5.2MARKET DYNAMICS52
FIGURE 20CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES52
5.2.1DRIVERS53
5.2.1.1Increasing government investments in cell-based research53
TABLE 1NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2019 (USD MILLION)53
5.2.1.2Rising incidence of chronic and infectious diseases54
5.2.1.3Large number of oncology-related cell therapy clinical trials54
FIGURE 21CANCER CELL THERAPY PIPELINE (MARCH 2019–MARCH 2020)55
5.2.1.4Increasing GMP certifications for cell therapy production facilities55
TABLE 2EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP55
5.2.2RESTRAINTS56
5.2.2.1High cost of cell-based research and low success rate56
TABLE 3COST OF CELL THERAPY EQUIPMENT56
5.2.2.2Dearth of skilled professionals56
5.2.3OPPORTUNITIES57
5.2.3.1Emergence of iPSCs as alternatives to ESCs57
5.2.3.2Increased focus on personalized medicine57
5.2.3.3Increasing public-private partnerships for development of cell therapies58
5.2.3.4Emerging Asian markets58
5.2.4CHALLENGES58
5.2.4.1Survival of small players and new entrants58
5.3TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES59
FIGURE 22REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS59
5.4INDICATIVE PRICING MODEL ANALYSIS59
TABLE 4PRICING ANALYSIS OF CELL THERAPY PRODUCTS59
5.5TECHNOLOGY ANALYSIS60
5.6VALUE CHAIN ANALYSIS60
FIGURE 23VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE60
5.7SUPPLY CHAIN ANALYSIS61
FIGURE 24CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS62
5.8ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET62
FIGURE 25ECOSYSTEM ANALYSIS62
TABLE 5SUPPLY CHAIN ECOSYSTEM63
5.9KEY CONFERENCES AND EVENTS IN 2022–202364
TABLE 6CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS64
5.10REGULATORY ANALYSIS65
5.10.1NORTH AMERICA65
TABLE 7NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES65
5.10.2EUROPE66
TABLE 8EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES66
5.10.3ASIA PACIFIC67
TABLE 9ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES67
5.10.4REST OF THE WORLD68
TABLE 10REST OF THE WORLD: REGULATORY LANDSCAPE FOR CELL THERAPIES68
5.11PORTER’S FIVE FORCES ANALYSIS69
TABLE 11CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS69
5.11.1THREAT OF NEW ENTRANTS69
5.11.2THREAT OF SUBSTITUTES69
5.11.3BARGAINING POWER OF SUPPLIERS69
5.11.4BARGAINING POWER OF BUYERS69
5.11.5DEGREE OF COMPETITION69
5.12PATENT ANALYSIS70
FIGURE 26PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JANUARY 2012–JULY 202270
TABLE 12INDICATIVE LIST OF PATENTS IN CELL THERAPY TECHNOLOGIES MARKET70
5.13KEY STAKEHOLDERS AND BUYING CRITERIA71
5.13.1KEY STAKEHOLDERS IN BUYING PROCESS71
FIGURE 27INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF CELL THERAPY PRODUCTS71
5.13.2BUYING CRITERIA FOR CELL THERAPY PRODUCTS72
FIGURE 28KEY BUYING CRITERIA FOR END USERS72
6CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT73
6.1INTRODUCTION74
TABLE 13CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)74
6.2MEDIA, SERA, AND REAGENTS74
6.2.1MEDIA, SERA, AND REAGENTS ARE INTEGRAL PARTS OF CELL PROCESSING74
TABLE 14CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY REGION, 2020–2027 (USD MILLION)75
TABLE 15NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)75
TABLE 16EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)75
TABLE 17ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)76
6.3CELL ENGINEERING PRODUCTS76
6.3.1AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS SUPPORTS MARKET GROWTH76
TABLE 18CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)76
TABLE 19NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)77
TABLE 20EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)77
TABLE 21ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)77
6.4CELL CULTURE VESSELS78
6.4.1CELL CULTURE VESSELS ARE WIDELY USED FOR CELL GROWTH78
TABLE 22CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY REGION, 2020–2027 (USD MILLION)78
TABLE 23NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)78
TABLE 24EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)79
TABLE 25ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)79
6.5EQUIPMENT79
TABLE 26CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)80
TABLE 27NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)80
TABLE 28EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)80
TABLE 29ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 30CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY TYPE, 2020–2027 (USD MILLION)81
6.5.1CELL PROCESSING EQUIPMENT81
6.5.1.1Cell processing equipment segment dominates cell therapy equipment market81
TABLE 31CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)82
TABLE 32NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)82
TABLE 33EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)82
TABLE 34ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)83
6.5.2SINGLE-USE EQUIPMENT83
6.5.2.1Benefits of single-use equipment have ensured end-user demand83
TABLE 35CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)83
TABLE 36NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 37EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 38ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)84
6.5.3OTHER EQUIPMENT85
TABLE 39CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)85
TABLE 40NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)85
TABLE 41EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)86
TABLE 42ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)86
6.6SYSTEMS AND SOFTWARE86
6.6.1SYSTEMS AND SOFTWARE ARE USED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING86
TABLE 43CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY REGION, 2020–2027 (USD MILLION)87
TABLE 44NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)87
TABLE 45EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)87
TABLE 46ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)88

6.7OTHER PRODUCTS88
TABLE 47CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY REGION, 2020–2027 (USD MILLION)88
TABLE 48NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)89
TABLE 49EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)89
TABLE 50ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)89
7CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS90
7.1INTRODUCTION91
TABLE 51CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)91
7.2CELL PROCESSING91
7.2.1CELL PROCESSING MAKES WIDE USE OF CELL THERAPY INSTRUMENTS91
TABLE 52CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2020–2027 (USD MILLION)91
TABLE 53NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)92
TABLE 54EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)92
TABLE 55ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)92
7.3CELL PRESERVATION, DISTRIBUTION, AND HANDLING93
7.3.1INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH93
TABLE 56CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2020–2027 (USD MILLION)93
TABLE 57NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)93
TABLE 58EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)94
TABLE 59ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)94
7.4PROCESS MONITORING AND QUALITY CONTROL95
7.4.1PROCESS MONITORING IS ESSENTIAL TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING95
TABLE 60CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY REGION, 2020–2027 (USD MILLION)95
TABLE 61NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)96
TABLE 62EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)96
TABLE 63ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)96
8CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE97
8.1INTRODUCTION98
TABLE 64CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)98
8.2T CELLS98
8.2.1RESEARCH CONDUCTED ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH98
TABLE 65CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2020–2027 (USD MILLION)99
TABLE 66NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)99
TABLE 67EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)99
TABLE 68ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)100
8.3STEM CELLS100
8.3.1INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE SEGMENT GROWTH100
TABLE 69CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2020–2027 (USD MILLION)101
TABLE 70NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)101
TABLE 71EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)101
TABLE 72ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)102
8.4OTHER CELLS102
TABLE 73CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2020–2027 (USD MILLION)102
TABLE 74NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)103
TABLE 75EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)103
TABLE 76ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)103
9CELL THERAPY TECHNOLOGIES MARKET, BY END USER104
9.1INTRODUCTION105
TABLE 77CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)105
9.2BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES105
9.2.1RISING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE SEGMENT GROWTH105
TABLE 78CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)106
TABLE 79NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)106
TABLE 80EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)106
TABLE 81ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)107
9.3CROS AND CMOS107
9.3.1RISING FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH107
TABLE 82CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY REGION, 2020–2027 (USD MILLION)107
TABLE 83NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)108
TABLE 84EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)108
TABLE 85ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)108
9.4RESEARCH INSTITUTES AND CELL BANKS109
9.4.1MARKET GROWTH IS SUPPORTED BY RISING RESEARCH ACTIVITY109
TABLE 86CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY REGION, 2020–2027 (USD MILLION)109
TABLE 87NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)109
TABLE 88EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)110
TABLE 89ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)110
10CELL THERAPY TECHNOLOGIES MARKET, BY REGION111
10.1INTRODUCTION112
TABLE 90CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2020–2027 (USD MILLION)112
10.2NORTH AMERICA112
FIGURE 29NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT113
TABLE 91NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)113
TABLE 92NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)114
TABLE 93NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)114
TABLE 94NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)114
TABLE 95NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)115
TABLE 96NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)115
10.2.1US115
10.2.1.1Increasing R&D activities to support market growth115
TABLE 97US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)116
TABLE 98US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)116
TABLE 99US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)116
TABLE 100US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)117
TABLE 101US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)117
10.2.2CANADA117
10.2.2.1Increasing government funding to drive adoption of cell therapy instruments117
TABLE 102CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)118
TABLE 103CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)118
TABLE 104CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)118
TABLE 105CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)119
TABLE 106CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)119
10.3EUROPE119
TABLE 107EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)120
TABLE 108EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)120
TABLE 109EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)120
TABLE 110EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)121
TABLE 111EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)121
TABLE 112EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)121
10.3.1GERMANY122
10.3.1.1Germany holds largest share of European market122
TABLE 113GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)122
TABLE 114GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)122
TABLE 115GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)123
TABLE 116GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)123
TABLE 117GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)123
10.3.2UK124
10.3.2.1Favorable funding and investment scenario to drive market growth124
TABLE 118UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)124
TABLE 119UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)124
TABLE 120UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)125
TABLE 121UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)125
TABLE 122UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)125
10.3.3FRANCE126
10.3.3.1Availability of government and private support to drive market growth126
TABLE 123FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)126
TABLE 124FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)127
TABLE 125FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)127
TABLE 126FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)127
TABLE 127FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)128
10.3.4ITALY128
10.3.4.1Initiatives favoring cell and gene therapy development to support market growth128
TABLE 128ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)129
TABLE 129ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)129
TABLE 130ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)129
TABLE 131ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)130
TABLE 132ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)130
10.3.5SPAIN130
10.3.5.1Increasing funding from private and public organizations to aid market growth130
TABLE 133SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)131
TABLE 134SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)131
TABLE 135SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)131
TABLE 136SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)132
TABLE 137SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)132
10.3.6REST OF EUROPE132
TABLE 138ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)133
TABLE 139ROE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)133
TABLE 140ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)133
TABLE 141ROE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)134
TABLE 142ROE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)134
10.4ASIA PACIFIC134
FIGURE 30ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT135
TABLE 143ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)135
TABLE 144ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)136
TABLE 145ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)136
TABLE 146ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)136
TABLE 147ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)137
TABLE 148ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)137
10.4.1CHINA137
10.4.1.1Increasing cell therapy-based trials to support market growth137
TABLE 149CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)138
TABLE 150CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)138
TABLE 151CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)138
TABLE 152CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)139
TABLE 153CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)139
10.4.2JAPAN139
10.4.2.1Rising geriatric population and growing disease prevalence to drive market growth139
TABLE 154JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025140
TABLE 155JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)140
TABLE 156JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)140
TABLE 157JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)141
TABLE 158JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)141
TABLE 159JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)141
10.4.3INDIA142
10.4.3.1Favorable government regulations to support market growth142
TABLE 160INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)142
TABLE 161INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)142
TABLE 162INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)143
TABLE 163INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)143
TABLE 164INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)143
10.4.4REST OF ASIA PACIFIC144
TABLE 165ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)144
TABLE 166ROAPAC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)144
TABLE 167ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)145
TABLE 168ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)145
TABLE 169ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)145
10.5LATIN AMERICA146
10.5.1AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET GROWTH146
TABLE 170LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)146
TABLE 171LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)146
TABLE 172LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)147
TABLE 173LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)147
TABLE 174LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)147
10.6MIDDLE EAST AND AFRICA148
10.6.1INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET GROWTH148
TABLE 175MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)148
TABLE 176MIDDLE EAST AND AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)148
TABLE 177MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)149
TABLE 178MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)149
TABLE 179MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)149
11COMPETITIVE LANDSCAPE150
11.1INTRODUCTION150
11.2RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS150
FIGURE 31CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED151
11.3MARKET SHARE ANALYSIS152
FIGURE 32CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)152
TABLE 180CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION152
11.4REVENUE ANALYSIS153
FIGURE 33REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)153
11.5COMPANY EVALUATION MATRIX154
FIGURE 34CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX, 2021154
11.5.1STARS155
11.5.2EMERGING LEADERS155
11.5.3PERVASIVE PLAYERS155
11.5.4PARTICIPANTS155
11.6COMPANY EVALUATION MATRIX: START-UPS/SMES156
FIGURE 35CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021156
11.6.1PROGRESSIVE COMPANIES157
11.6.2STARTING BLOCKS157
11.6.3RESPONSIVE COMPANIES157
11.6.4DYNAMIC COMPANIES157
11.6.5COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS157
TABLE 181CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UPS/SMES157
TABLE 182CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES159
11.7COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS159
11.7.1COMPANY FOOTPRINT (25 COMPANIES)159
TABLE 183COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS159
11.7.2PRODUCT FOOTPRINT (25 COMPANIES)160
TABLE 184PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS160
11.7.3PROCESS FOOTPRINT (25 COMPANIES)161
TABLE 185PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS161
11.7.4REGIONAL FOOTPRINT (25 COMPANIES)162
TABLE 186REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS162
11.8COMPETITIVE SCENARIO AND TRENDS163
11.8.1PRODUCT LAUNCHES163
TABLE 187CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES (JANUARY 2019–JULY 2022)163
11.8.2DEALS164
TABLE 188CELL THERAPY TECHNOLOGIES MARKET: DEALS (JANUARY 2019–JULY 2022)164
11.8.3OTHER DEVELOPMENTS164
TABLE 189CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS (JANUARY 2019–JULY 2022)164
12COMPANY PROFILES165
12.1KEY PLAYERS165
(Business Overview, Products Offered, Recent Developments, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats)*
12.1.1THERMO FISHER SCIENTIFIC, INC.165
TABLE 190THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW165
FIGURE 36THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT166
12.1.2MERCK KGAA170
TABLE 191MERCK KGAA: BUSINESS OVERVIEW170
FIGURE 37MERCK KGAA: COMPANY SNAPSHOT171
12.1.3DANAHER CORPORATION174
TABLE 192DANAHER CORPORATION: BUSINESS OVERVIEW174
FIGURE 38DANAHER CORPORATION: COMPANY SNAPSHOT175
12.1.4LONZA GROUP179
TABLE 193LONZA GROUP: BUSINESS OVERVIEW179
FIGURE 39LONZA GROUP: COMPANY SNAPSHOT180
12.1.5SARTORIUS AG182
TABLE 194SARTORIUS AG: BUSINESS OVERVIEW182
FIGURE 40SARTORIUS AG: COMPANY SNAPSHOT183
12.1.6TERUMO BCT, INC.185
TABLE 195TERUMO CORPORATION: BUSINESS OVERVIEW185
FIGURE 41TERUMO CORPORATION: COMPANY SNAPSHOT185
12.1.7BECTON, DICKINSON AND COMPANY187
TABLE 196BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW187
FIGURE 42BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT188
12.1.8FRESENIUS SE & CO. KGAA189
TABLE 197FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW189
FIGURE 43FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT189
12.1.9AVANTOR, INC.191
TABLE 198AVANTOR, INC.: BUSINESS OVERVIEW191
FIGURE 44AVANTOR, INC.: COMPANY SNAPSHOT192
12.1.10BIO-TECHNE CORPORATION194
TABLE 199BIO-TECHNE CORPORATION: BUSINESS OVERVIEW194
FIGURE 45BIO-TECHNE CORPORATION: COMPANY SNAPSHOT195
12.1.11CORNING INCORPORATED198
TABLE 200CORNING INCORPORATED: BUSINESS OVERVIEW198
FIGURE 46CORNING INCORPORATED: COMPANY SNAPSHOT199
12.1.12FUJIFILM IRVINE SCIENTIFIC200
TABLE 201FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW200
FIGURE 47FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT201
12.1.13MAXCYTE, INC.202
TABLE 202MAXCYTE: BUSINESS OVERVIEW202
FIGURE 48MAXCYTE: COMPANY SNAPSHOT202
*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12.2OTHER PLAYERS204
12.2.1WERUM IT SOLUTIONS204
12.2.2ROOSTERBIO, INC.204
12.2.3SIRION BIOTECH GMBH205
12.2.4TRAKCEL205
12.2.5L7 INFORMATICS206
12.2.6MILTENYI BIOTEC206
12.2.7STEMCELL TECHNOLOGIES INC.207
12.2.8GPI IBERIA (FORMERLY HEMASOFT)209
12.2.9MAK-SYSTEM209
12.2.10ORGANABIO, LLC210
12.2.11IXCELLS BIOTECHNOLOGIES210
12.2.12WILSON WOLF MANUFACTURING CORPORATION211
13APPENDIX212
13.1DISCUSSION GUIDE212
13.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL215
13.3CUSTOMIZATION OPTIONS217
13.4RELATED REPORTS217
13.5AUTHOR DETAILS218

Report Title: Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW